1. Home
  2. BKE vs WVE Comparison

BKE vs WVE Comparison

Compare BKE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Buckle Inc. (The)

BKE

Buckle Inc. (The)

HOLD

Current Price

$50.75

Market Cap

2.5B

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$13.38

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKE
WVE
Founded
1948
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
BKE
WVE
Price
$50.75
$13.38
Analyst Decision
Hold
Strong Buy
Analyst Count
1
15
Target Price
$55.00
$30.73
AVG Volume (30 Days)
308.0K
2.2M
Earning Date
01-01-0001
05-29-2026
Dividend Yield
8.36%
N/A
EPS Growth
N/A
N/A
EPS
2.55
N/A
Revenue
$1,217,689,000.00
$3,704,000.00
Revenue This Year
$7.42
$16.76
Revenue Next Year
$2.75
$149.85
P/E Ratio
$20.58
N/A
Revenue Growth
N/A
149.43
52 Week Low
$33.12
$5.28
52 Week High
$61.69
$21.73

Technical Indicators

Market Signals
Indicator
BKE
WVE
Relative Strength Index (RSI) 40.20 45.40
Support Level $47.15 $12.53
Resistance Level $56.56 $14.56
Average True Range (ATR) 1.48 0.78
MACD -0.16 -0.02
Stochastic Oscillator 15.79 20.34

Price Performance

Historical Comparison
BKE
WVE

About BKE Buckle Inc. (The)

Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: